AzTrials
AzTrials

Sickle Cell RetinopathyRAVOSNCT06396403

The Role of Red Cell Characteristics, Angiogenesis, Viscosity and Oxygenation in the Pathophysiology of Sickle Cell Related Retinopathy

An observational study of Sickle Cell Retinopathy and Sickle Cell Disease, run by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) at 1 site in Netherlands.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Objective: to gain insight in the pathogenesis, to identify biomarkers to recognize patients at risk for proliferative SCR and to investigate its associations with clinical and laboratory characteristics. Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
Collection of venous blood samples
How many people
68 participants
Where
1 siteNetherlands
Study dates
13 Jun 2023to 17 Jun 2024
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Adult patients with sickle cell disease (SCD) with the HbSS or HbSC genotype, attending the outpatient Sickle Cell Clinic from the Amsterdam UMC.

Who may be able to join

  • Minimum age of 18 years
  • HbSC or HbSS genotype
  • Recent ophthalmologic examination (up to 2 years prior) or (willingness to attend) upcoming examination

Who cannot join

  • Age below 18 years
  • Genotype other than HbSC or HbSS
  • No recent ophthalmologic examination and no intention to visit the outpatient clinic for ophthalmic and hematologic examination
  • Participation in trials with either crizanlizumab, voxelotor or mitapivat.

Trial locations and contacts

1 site in 1 country.

Netherlands1 site
  • Amsterdam UMC

    Amsterdam, North Holland, 1105AZ

Other trials in Netherlands

About this study

Objective:

to gain insight in the pathogenesis, to identify biomarkers to recognize patients at risk for proliferative SCR and to investigate its associations with clinical and laboratory characteristics.

Endpoints:

The investigators will determine the difference in the above named parameters between patients with and without PSCR

Study design:

This case control study will include adult sickle cell disease patients with the HbSS or HbSC genotype. For both genotypes, 20 patients without sickle cell retinopathy (SCR) and 20 patients with PSCR will be included, resulting in a total of 80 patients. Venous blood samples and retinal imaging scans will be collected for each included patient.

Read the detailed description

Rationale:

Sickle cell disease (SCD) is characterized by chronic hemolysis and recurrent microvascular occlusion, resulting in ischemia and organ damage1. This study focuses on retinal damage: sickle cell retinopathy (SCR). SCR results from ischemic vascular disease and secondary angiogenesis, but it is unknown which factors play a significant role in the pathogenesis. Studies on this subject are still in an early phase3,4. Our aim is to gain insight in the pathogenesis, to identify biomarkers to recognize patients at risk for proliferative SCR and to investigate its associations with clinical and laboratory characteristics. The focus of our study is aimed at evaluation of innovative biomarkers of angiogenesis, whole blood viscosity and innovative characterization of red blood cell parameters such as deformability, adhesiveness and "point of sickling" as can be measured ex vivo by the Oxygenscan (i.e.: red cell sickling capacity). The Oxygenscan is a new method to calculate the deformability of red blood cells as a function of the partial pressure of oxygen. These novel parameters will be related to clinical characteristics observed in these patients and specific markers of early retinopathy such as vessel density and macula thinning assessed by OCT angiography.

Objective:

The objective of this study is to gain insight in the pathogenesis, to identify the role of red cell characteristics, markers of angiogenesis, retinal oxygenation and whole blood viscosity in the development of proliferative SCR and to investigate its associations with clinical and laboratory characteristics.

Study design:

Case control study

Study population:

Adult patients with sickle cell disease (SCD) with a HbSS or HbSC genotype. For both genotypes, 20 patients without SCR and 20 patients with proliferative SCR will be included. The total amount of included patients will be 80 patients.

Intervention:

venous blood samples (1 EDTA tube and 1 PECT tubes of 4-5 mL each) will be collected from all included patients, who will be requested to fast 8 hours before the collection of blood. If fasting is not desired/possible, a low-fat breakfast can be consumed.

Main study parameters/endpoints: (1) The difference in red blood cell characteristics (point of sickling) between patients with and without PSCR, (2) The difference in plasma levels of parameters representing the level of systemic angiogenesis activity (CD105, VEGF, CTGF and angiopoietin-2) between patients with and without PSCR, (3) The difference in oxygenation of the retina by assessing the vessel density with angio-OCT and by assessing the oxygen saturation in the retinal arterioles and venules with the Oxymap scan in patients with and without PSCR, (4) The difference in whole blood viscosity between patients with and without PSCR

Nature and extent of the burden and risks associated with participation, benefit and group relatedness:

Data from recent ophthalmologic and hematologic examinations will be collected. If no recent ophthalmologic examination is available and no further appointments were made yet, the patient will be contacted to visit the outpatient clinic for a new appointment. Since the appointments are in accordance with the general screening schedule according to the Dutch Guidelines for Sickle Cell Disease, these investigations are no extra burden for the patients. Venous blood samples will be obtained by venepuncture, preferably during the routine venepuncture for scheduled hematological visits (so the only extra burden consists of the extra blood aliquots that have be drawn to answer the research questions). Venepuncture is a safe and frequently used procedure in the routine care of patients with sickle cell disease. Due to the request to fast before the venepuncture, appointments will only be scheduled in the morning in order to reduce the burden on the patient as much as possible.

Being tested
Collection of venous blood samples
Medical subject headings
Anemia, Sickle Cell

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Collection of venous blood samplesOther

    collection includes 1 EDTA tube and 1 Sarstedt S-Monovette tube of 5 mL

Study groups in NCT06396403
Study groupRoleWhat they receive
HbSS patients without SCRAdult sickle cell patients with the HbSS genotype and without sickle cell retinopathy
Receives: Other: Collection of venous blood samples
HbSS patients with PSCRAdult sickle cell patients with the HbSS genotype and proliferative sickle cell retinopathy
Receives: Other: Collection of venous blood samples
HbSC patients without SCRAdult sickle cell patients with the HbSC genotype and without sickle cell retinopathy
Receives: Other: Collection of venous blood samples
HbSC patients with PSCRAdult sickle cell patients with the HbSC genotype and proliferative sickle cell retinopathy
Receives: Other: Collection of venous blood samples

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Differences in Red blood cell characteristics (Oxygenscan)

    The difference in red blood cell characteristics (point of sickling) between patients with and without PSCR in both genotypes

    Measured: Immediately after the venepuncture

  2. Differences in Angiogenesis biomarkers

    The difference in plasma levels of parameters representing the level of systemic angiogenesis activity (CD105, VEGF, CTGF and angiopoietin-2) between patients with and without PSCR in both genotypes

    Measured: Immediately after the venepuncture

  3. Differences in Retinal Oxygenation

    The difference in oxygenation of the retina by assessing the vessel density with angio- OCT and by assessing the oxygen saturation in the retinal arterioles and venules with the Oxymap scan in patients with and without PSCR in both genotypes

    Measured: Immediately after the venepuncture

  4. Differences in Whole blood viscosity

    The difference in whole blood viscosity between patients with and without PSCR in both genotypes

    Measured: Immediately after the venepuncture

Secondary outcomes (4)
  1. Associations between Oxygenation parameters and Red blood cell characteristics

    Association between retinal vessel density assessed by OCT-angiography, oxygen saturation assessed by an Oxymap scan and red blood cell characteristics (deformity, adhesion and point of sickling upon hypoxia)

    Measured: Immediately after the venepuncture

  2. Associations between sex, age, and genotype and the biomarkers of angiogenesis

    Association between sex, age, and genotype and the biomarkers of angiogenesis

    Measured: Immediately after the venepuncture

  3. Association between hemoglobin, and HbF and biomarkers of angiogenesis

    Association between hemoglobin, and HbF and biomarkers of angiogenesis

    Measured: Immediately after the venepuncture

  4. Associations between whole blood viscosity and genotype

    Associations between whole blood viscosity and genotype

    Measured: Immediately after the venepuncture

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted2 May 2024
  2. Study start13 Jun 2023
  3. Primary completion17 Jun 2024
  4. Study completion17 Jun 2024

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case-control
Time perspective
Cross-sectional
Enrolment
68 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06396403
Sponsor's protocol ID
NL81111.018.22
Acronym
RAVOS
Status last verified
Nov 2024
First submitted
24 Apr 2024
Last updated
15 Nov 2024
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

An observational study of Sickle Cell Retinopathy and Sickle Cell Disease, run by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) at 1 site in Netherlands.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 15 Nov 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Netherlands. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Differences in Red blood cell characteristics (Oxygenscan) (time frame: Immediately after the venepuncture). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Nov 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in